Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.
about
Galactose 6-O-sulfotransferases are not required for the generation of Siglec-F ligands in leukocytes or lung tissueMice deficient in the St3gal3 gene product α2,3 sialyltransferase (ST3Gal-III) exhibit enhanced allergic eosinophilic airway inflammationA Player and Coordinator: The Versatile Roles of Eosinophils in the Immune SystemNovel Therapies for Eosinophilic DisordersEosinophil apoptosis and clearance in asthmaMechanism of Siglec-8-mediated cell death in IL-5-activated eosinophils: role for reactive oxygen species-enhanced MEK/ERK activationEngineered nanomaterial exposure and the risk of allergic diseaseImmunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis.Siglec-mediated regulation of immune cell function in disease.Novel targeted therapies for eosinophil-associated diseases and allergyHypereosinophilic Syndrome.Role of siglecs and related glycan-binding proteins in immune responses and immunoregulationExpression of ligands for Siglec-8 and Siglec-9 in human airways and airway cells.Eosinophils: changing perspectives in health and disease.Biologic therapies targeting eosinophils: current status and future prospects.Endogenous airway mucins carry glycans that bind Siglec-F and induce eosinophil apoptosis.Current and future biomarkers in allergic asthma.Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD).Effect of anti-siglec-f antibody and reactive oxygen species blocking on histamine release in urinary bladder of ovalbumin-treated mice.Sialic acids and autoimmune disease.Glycobiology simplified: diverse roles of glycan recognition in inflammationStructural basis for sulfation-dependent self-glycan recognition by the human immune-inhibitory receptor Siglec-8Diagnosis and management of eosinophilic asthma: a US perspective.Targeting eosinophils in allergy, inflammation and beyond.Eosinophil apoptosis as a therapeutic target in allergic asthma.Eosinophils and mast cells as therapeutic targets in pediatric functional dyspepsiaClinical implications and pathogenesis of esophageal remodeling in eosinophilic esophagitis.Biological Modulators in Eosinophilic Diseases.Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.Eosinophils in mucosal immune responsesTherapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.The transcriptional program, functional heterogeneity, and clinical targeting of mast cells.Regulation of airway inflammation by Siglec-8 and Siglec-9 sialoglycan ligand expression.Is there a future for biologics in the management of chronic rhinosinusitis?Improving the diagnosis of eosinophilic asthma.Targeted delivery of mycobacterial antigens to human dendritic cells via Siglec-7 induces robust T cell activationThe Biology of Eosinophils and Their Role in Asthma.Homeostatic Eosinophils: Characteristics and Functions.Cell type-specific glycosylation of Orai1 modulates store-operated Ca2+ entry.Histamine Release from Mast Cells and Basophils.
P2860
Q24622257-C9A3889C-EF6B-42FB-A128-09C4154AD3A2Q24624727-541B9849-CAF7-4335-95CF-AD03D9D3DCD7Q26745903-8A7E6234-CFC7-4260-AC95-663A3F23C064Q26799600-28B7106A-AB8C-4DC6-B906-AC0DC1A572BAQ26852263-ACBB5489-06FA-49C2-9218-E9F7EFA18CDEQ28290873-C3D4430E-3FA4-4334-BD83-90C283D99F59Q28389510-7DB2DA95-DD31-4073-BD07-3B2B512CBA7BQ33913202-EA10E48C-8736-43AB-BCC7-682E14E475B7Q34314957-5B85FB60-CB9C-4418-8B08-0AE424020896Q34444620-F3AF794A-EC1F-465D-8D3C-265659C17562Q34498306-4CBEEB4E-DC50-4BE2-A1CA-EA8B1EA68F42Q35164415-487B1563-1D3D-4560-A327-55262BD2A358Q35165332-60463ADD-8EF7-416C-8C28-CA10B46D653FQ35170969-D602E4C1-E85F-45C4-8114-E7EAF567291DQ35565533-72F4B2C5-D001-44CE-9A27-1C909997A1C5Q35612914-031EF509-8774-40C0-A309-F07915362F49Q35878914-B5F99A43-93F0-495D-A973-5BCD572D5590Q36206063-11D6C1CD-2016-4AB3-B5E4-E71BD78D1CA8Q36313180-F6A712D2-A101-4FE4-B9BB-121CC2372B68Q36625410-59EE3454-9596-4DD5-BB65-54F356FCE2A3Q37111287-BB0106D8-EB7B-46F8-ACB7-18AB25B065E7Q37126813-DF72572D-3D0A-4C43-A2A3-67CB47DD4B8BQ37708682-F0D56CC6-EEC3-4255-9E0F-CA5E04A3B44EQ38075409-830BFD33-37F7-4733-B2EE-97355587D953Q38154740-6088E4C5-329A-46FA-9426-7235678CB396Q38160491-61F2AA68-6A57-43CE-960E-85C7D7009882Q38210619-E35FF52F-D9BD-4207-8F41-16389F0765F2Q38240474-1AC53D55-0ADC-4CD7-A80B-9AB06D96104CQ38285397-B1DED555-4847-40AF-A684-FC410FAB57B1Q38390424-937FC873-94CD-46A5-AD7B-B353F38290FFQ38598881-1D5097B1-E03C-4349-AECB-75110D6C3CB9Q38642037-4BB8FDF5-35A7-439E-A44F-A5F82B044A96Q38676224-95370D4E-FB5A-4F91-9AAF-186C8B2CFD56Q38814643-83FEEBBD-3104-4191-9320-A23AD51C4D9BQ38821540-298CE222-0096-4763-8B5E-493858E41163Q38977473-43EEA079-9630-4F72-AB34-7C8B08DD10ECQ39438308-12D2B995-C5CE-49B7-9280-1EB5955CD7C1Q39458566-939F2B17-229B-4744-8110-31D52CB591BBQ39937828-E1229156-2053-4CE1-AFE4-F147E1EFD29EQ40282553-FFF52C7E-9837-4940-B067-B4AFF066F74E
P2860
Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.
@ast
Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.
@en
type
label
Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.
@ast
Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.
@en
prefLabel
Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.
@ast
Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.
@en
P2093
P2860
P1476
Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.
@en
P2093
Bruce S Bochner
James C Paulson
Norihito Kawasaki
P2860
P304
P356
10.1016/J.PHARMTHERA.2012.06.005
P577
2012-06-27T00:00:00Z